Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The company is headquartered in Los Altos, California and currently employs 21 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
06/30/2026
03/31/2026
12/31/2025
09/30/2025
06/30/2025
Ingresos
0
0
0
0
0
0
Crecimiento de los Ingresos (YoY)
--
--
--
--
--
--
Costo de los ingresos
--
--
--
--
--
--
Utilidad bruta
--
--
--
--
--
--
Venta, General y Administración
23
7
6
4
4
5
Investigación y Desarrollo
9
2
1
2
2
1
Gastos de Operación
33
10
8
7
7
6
Otras Ingresos (Gastos) No Operativos
-3
7
-4
-7
1
0
Ingreso antes de impuestos
-35
-1
-12
-14
-6
-6
Gasto por Impuesto a la Renta
--
--
--
--
--
--
Ingreso Neto
-35
-1
-12
-14
-6
-6
Crecimiento de la Utilidad Neta
13%
-83%
--
-33%
50%
-300%
Acciones en Circulación (Diluidas)
26.91
26.91
23.9
21.43
18.06
12.3
Cambio de Acciones (YoY)
119%
119%
93%
103%
103%
31%
EPS (Diluido)
-1.3
-0.06
-0.53
-0.68
-0.33
-0.52
Crecimiento de EPS
-49%
-88%
-1,402%
-66%
-28%
-262%
Flujo de efectivo libre
-27
-7
-6
-8
-5
-8
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
--
--
--
--
--
--
Margen de operación
0%
0%
0%
0%
0%
0%
Margen de beneficio
0%
0%
0%
0%
0%
0%
Margen de flujo de caja libre
0%
0%
0%
0%
0%
0%
EBITDA
-33
-10
-8
-7
-7
-6
Margen de EBITDA
0%
0%
0%
0%
0%
0%
D&A para EBITDA
0
0
0
0
0
0
EBIT
-33
-10
-8
-7
-7
-6
Margen de EBIT
0%
0%
0%
0%
0%
0%
Tasa de Impuesto Efectiva
--
--
--
--
--
--
Follow-Up Questions
Unicycive Therapeutics Inc'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Unicycive Therapeutics Inc'in toplam varlıkları $0 olup, net pérdida $0'dir.
UNCY'ün temel finansal oranları nelerdir?
Unicycive Therapeutics Inc'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.
Unicycive Therapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
El segmento de ingresos más grande es Unicycive Therapeutics Inc, con unos ingresos de Novel Therapies en el último informe de ganancias. En cuanto a la geografía, United States es el mercado principal para Unicycive Therapeutics Inc, con unos ingresos de 675,000.
Unicycive Therapeutics Inc kârlı mı?
no, son mali tablolara göre Unicycive Therapeutics Inc'in net pérdida $0'dir.
Unicycive Therapeutics Inc'in herhangi bir yükümlülüğü var mı?
no, Unicycive Therapeutics Inc'in yükümlülüğü 0'dir.
Unicycive Therapeutics Inc'in tedavüldeki hisse sayısı kaçtır?
Unicycive Therapeutics Inc'in toplam tedavüldeki hisse sayısı 0'dir.